Selank 15mg — Vial Spec, Reconstitution Math & COA

Overview of Selank 15mg Research Vials and Laboratory Demand

A 15mg vial of Selank contains 15 milligrams of high-purity, lyophilized synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) combined with a stabilizing buffer matrix. This specific mass yield is engineered for high-throughput screening environments, long-term animal cohort studies, and automated liquid handling systems where frequent vial transitions introduce analytical variance. High-density laboratory protocols benefit from reduced container-to-container variability when executing multi-week experimental series.

While PX1 Research maintains stock of standard catalog sizes such as Selank 10mg, the 15mg format is frequently requested by institutional laboratories conducting high-volume comparative trials. Researchers exploring our broad catalog of all peptides select 15mg configurations to minimize shipping frequencies and streamline stock solution preparation across complex assay panels.

Step-by-Step Reconstitution Math for 15mg Formulations

Accurate concentration calculations are vital when transitioning a 15mg lyophilized cake into a liquid state. Because the total active solute is fixed at 15,000 micrograms (mcg), the final concentration per microliter or milliliter depends entirely on the volume of bacteriostatic water or sterile diluent introduced into the glass septum vial.

When adding 1.0 mL of diluent, the resulting working concentration is exactly 15.0 mg/mL (15.0 mcg/μL). If using a standard laboratory micro-pipette or U-100 graduations, a 10 μL aliquot yields 150 mcg of active solute. When introducing 2.0 mL of diluent, the concentration scales down to 7.5 mg/mL (7.5 mcg/μL), providing a 75 mcg yield per 10 μL volumetric draw. Adding 3.0 mL of diluent yields a working concentration of 5.0 mg/mL (5.0 mcg/μL), where 10 μL delivers 50 mcg of compound.

To verify complex volume adjustments, dilution ratios, or multi-vial master mix calculations, researchers can utilize the PX1 reconstitution calculator to eliminate manual rounding errors prior to benchwork.

Benchtop Reconstitution Protocol and Aliquot Planning

Reconstitution of Selank 15mg must be performed under strict aseptic conditions within a certified laminar flow hood. Before introducing diluent, allow the lyophilized vial to equilibrate to ambient room temperature (20°C to 25°C) to prevent atmospheric condensation from contaminating the cake upon stopper perforation. Sanitize the rubber septum using a 70% isopropyl alcohol swab.

Direct the diluent needle toward the inner glass wall of the vial rather than shooting liquid directly onto the lyophilized powder. The high kinetic force of direct stream impingement can denature delicate peptide chains or cause excessive foaming. Allow the diluent to trickle slowly down the glass, then gently swirl the vial in a circular motion until the solute dissolves completely. Never shake the vial. Once dissolved, partition the solution into single-use micro-aliquots using sterile microcentrifuge tubes to eliminate repeated freeze-thaw cycles that destabilize the peptide's tertiary structure.

Molecular Structure and Synthetic Production Metrics

Selank is a synthetic derivative of the human immunomodulatory tetrapeptide tuftsin (Thr-Lys-Pro-Arg), augmented at the C-terminus by a Pro-Gly-Pro motif that significantly enhances metabolic stability. Its molecular formula is C33H57N11O9, corresponding to a molecular weight of approximately 751.9 g/mol. The incorporation of the tripeptide tail protects the active core against rapid cleavage by circulating peptidases in ex vivo tissue preparations.

PX1 Research utilizes advanced Solid-Phase Peptide Synthesis (SPPS) protocols to construct Selank. The manufacturing process involves step-wise coupling of Fmoc-protected amino acids, followed by TFA cleavage and ether precipitation. The crude peptide undergoes multi-stage preparatory high-performance liquid chromatography (HPLC) to isolate the target sequence, ensuring chemical identity and removing truncated sequence impurities.

Preclinical Mechanisms of Action in Laboratory Models

In preclinical literature, Selank has been evaluated for its interactions with the central nervous system, neurotrophic pathways, and immune system signaling. Rodent studies indicate that Selank modulates allosteric GABAergic neurotransmission, binding to GABA-A receptor complexes without competing directly with classical benzodiazepine site ligands. In vitro assays demonstrate that this allosteric interaction helps stabilize neural firing rates under induced oxidative stress.

Furthermore, animal models demonstrate that Selank administration influences gene expression profiles associated with Brain-Derived Neurotrophic Factor (BDNF) in hippocampal tissues. Preclinical research also shows that Selank inhibits the enzymatic breakdown of endogenous enkephalins by blocking enkephalin-degrading enzymes in blood plasma assays, extending the bio-activity of native opioid peptides in controlled laboratory settings.

Comparative Analysis: Selank vs. Related Neuro-Active Compounds

When designing neurological or behavioral assays, investigators frequently compare Selank against other synthetic peptide analogues targeting central signaling cascades. For example, comparing Selank to Semax reveals distinct structural bases; while Selank is derived from tuftsin, Semax is derived from an ACTH(4-10) fragment. Consequently, Semax primarily targets melanocortin receptors and neurotrophin expression rather than allosteric GABA modulation.

Similarly, modified structural variants such as N-Acetyl Semax Amidate exhibit altered lipophilicity and blood-brain barrier permeability metrics in preclinical models compared to unmodified peptides. Researchers interested in broader central nervous system screening pathways can review detailed peptide profiles in our centralized research library or examine overall mechanisms across our dedicated Selank resource page.

Analytical Verification: ISO 17025 HPLC, MS, and Endotoxin Standards

To ensure reproducible experimental outcomes, every lot of Selank 15mg produced for PX1 Research undergoes rigorous verification in an independent ISO 17025 accredited analytical facility. Quality assurance requires verification of peptide purity via Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC), ensuring a purity threshold of ≥98.0%. Electrospray Ionization Mass Spectrometry (ESI-MS) confirms exact molecular mass matching the theoretical spectrum of 751.9 Da.

Because biological assays—particularly cell culture and central nervous system tissue preparations—are sensitive to bacterial contaminants, all fills are subject to Kinetic Chromogenic LAL (Limulus Amebocyte Lysate) testing to verify endotoxin levels remain strictly below <0.05 EU/mg. Investigators can access and download lot-specific analytical documentation directly via our public COA portal.

Selecting the Optimal Vial Size: 10mg vs. 15mg Considerations

Choosing between a standard 10mg vial and a high-yield 15mg vial depends primarily on assay duration, subject cohort size, and container stability requirements. Smaller 10mg vials are ideal for short-term pilot studies or initial dose-response mapping where reconstituted solution is consumed within 7 to 10 days, minimizing ambient degradation risks.

Conversely, 15mg vials offer superior unit economics and procedural efficiency for multi-animal longitudinal trials or automated high-throughput assays. By reconstituting a single 15mg vial rather than multiple lower-mass vials, laboratories reduce pipetting frequency, cut down on plastic consumable waste, and standardize baseline reagent concentrations across larger experimental blocks.

Lyophilization Integrity, Temperature Control, and Storage Protocols

Lyophilized Selank 15mg is shipped in temperature-controlled packaging originating from our primary distribution hubs in California and Arizona. Unopened vials stored in a desiccated environment at -20°C remain stable for up to 24 months from the date of synthesis. For immediate laboratory use, sealed vials may be held at 2°C to 8°C for up to 90 days without measurable degradation of active peptide content.

Following reconstitution with sterile bacteriostatic water (0.9% benzyl alcohol), the resulting solution must be stored at 2°C to 8°C and utilized within 21 to 28 days. Benzyl alcohol acts as a bacteriostatic agent preventing microbial growth, but long-term peptide exposure to aqueous environments eventually causes hydrolysis of sensitive peptide bonds. For long-term liquid storage, aliquoting frozen master stocks at -80°C is recommended.

Procurement, USA Manufacturing, and Institutional Accounts

PX1 Research manufactures all peptide sequences within cGMP-compliant facilities located in the United States. Orders placed Monday through Friday before 3:00 PM EST ship same-day from our dual dispatch facilities in California and Arizona, providing reliable delivery timelines for critical experimental schedules.

Principal investigators, university laboratories, and contract research organizations (CROs) requiring specialized bulk orders, custom fill sizes, or batch-dedicated analytical reservations can coordinate direct procurement arrangements through our dedicated wholesale institutional portal.